Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 15/20 | 0.57 |
| ▸ | APOB | P04114 | 3/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039772 | 0.96 | MTTP (0.53) | MTTPAPOBGAAPPARG | |
| SCHEMBL7041681 | 0.94 | MTTP (0.53) | MTTPAPOBPPARG | |
| SCHEMBL7035895 | 0.94 | MTTP (0.51) | MTTPAPOBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7035884 | 0.94 | MTTP (0.51) | MTTPAPOBGAAPPARG | |
| SCHEMBL7041096 | 0.94 | MTTP (0.51) | MTTPAPOBGAA | |
| SCHEMBL7037178 | 0.93 | MTTP (0.53) | MTTPAPOBPPARG | |
| SCHEMBL7041435 | 0.93 | MTTP (0.50) | MTTPAPOBGAAPPARG | |
| SCHEMBL7035871 | 0.93 | MTTP (0.50) | MTTPAPOBGAAPPARG | |
| SCHEMBL7043268 | 0.93 | MTTP (0.50) | MTTPAPOBGAAPPARG | |
| SCHEMBL7038333 | 0.93 | MTTP (0.50) | MTTPAPOBGAAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885APOB 1/4885CHRNB2 4509/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | MTTP 1/4885APOB 18/4885CHRNB2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.